Multitarget Stereotactic Electrophysiological Recording and Stimulation for Tourette Syndrome

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorBeijing Tiantan Hospital

About this trial

The goal of this clinical trial is to investigate the neural mechanisms underlying Tourette syndrome (TS) and see if personalized deep brain stimulation (DBS) can help reduce tics in TS patients and improve related issues like anxiety, attention problems, and obsessive-compulsive behaviors.

In this study, researchers will use stereoelectroencephalography (SEEG) and electrocorticography (ECoG) to record brain activity in key areas involved in movement and emotion, including the nucleus accumbens (NAc), anterior limb of the internal capsule (ALIC), insular cortex, anterior cingulate cortex (ACC), central medial thalamic nucleus (CM), globus pallidus internus (GPi), and motor cortex (M1). They will test stimulation in these areas to evaluate acute therapeutic effect for each target and to identify a new effective new target.

Later, participants will receive DBS treatment under three different conditions, each for 1 month to identify the optimal target:

1. Stimulation at the new target, 2. Stimulation at the CM, 3. Sham stimulation (does not actually stimulate).

Finally, DBS will be continued at the optimal target for an additional three months to confirm its therapeutic impact.

By analyzing the brain activity and comparing these conditions, the study will clarify the neural mechanisms underlying TS and learn which target works best to lower tics and improve overall quality of life for TS patients.

Eligibility criteria

Qualifiers

Age between 18 and 60 years.

A Yale Global Tic Severity Scale (YGTSS) total score greater than 35 (on a scale of 0-50) for at least 1 year, with a motor tic score of ≥15, and tics being the primary cause of disability.

Inadequate response to conservative treatments (standard pharmacological and behavioral therapy).

Disease duration of more than 1 year.

Disqualifiers

Presence of suicidal risk, defined as a score of ≥3 on the suicide-related items of the Hamilton Depression Rating Scale (HAMD).

History of drug or alcohol dependence within the past 6 months.

Abnormal brain structure as indicated by CT or MRI scans.

Presence of any condition that could lead to surgical failure or interfere with postoperative management.

Trial design

Treatments tested in this trial

  • New Target DBS
  • CM-DBS
  • Sham Stimulation

Treatment groups

5 Participants
are divided into 3 treatment groups

Sponsors and collaborators